Assess whether pediatric studies are necessary or waivable (014fc5)

Situation

Pediatric studies are necessary sits with pediatric-plan strategist because a CMO 483 that maps to the NDA CMC module hit a company with a CMC site change mid-review. Evidence is 505(b)(2) literature-to-product bridge table; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

Pediatric-plan strategist in a company with a CMC site change mid-review must choose Pediatric studies are necessary / Waivable using 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Pediatric-plan strategist can defend Pediatric studies are necessary from 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge.
• Pediatric-plan strategist cannot defend Pediatric studies are necessary from 505(b)(2) literature-to-product bridge table; Waivable is what the extract actually supports after a CMO 483 that maps to the NDA CMC module.
• A CMO 483 that maps to the NDA CMC module never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close pediatric studies are necessary.
• Two facts in 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module conflict for pediatric-plan strategist; hold this CMC and Development Pathways file.

Analysis required

• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a CMO 483 that maps to the NDA CMC module and write the one fact that would move pediatric studies are necessary for pediatric-plan strategist.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.